Literature DB >> 16467195

Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes.

Katja Wäldele1, Katrin Silbermann, Grit Schneider, Tobias Ruckes, Bryan R Cullen, Ralph Grassmann.   

Abstract

Human T cell leukemia virus type 1 (HTLV-1), the cause of adult T cell leukemia (ATL), induces clonal expansion of infected T-cells in nonleukemic individuals and immortalizes T cells in vitro. The resistance against apoptotic stimuli of these cells hints at a viral survival function in addition to a proliferation-stimulating activity. Here we describe the up-regulation of the antiapoptotic HIAP-1/CIAP-2 gene as a consistent phenotype of HTLV-1-transformed and ATL-derived cultures and its stimulation by the viral oncoprotein Tax. Cotransfections revealed a 60-fold increase of HIAP-1 promoter activity mediated by Tax mainly via nuclear factor-kappaB (NF-kappaB) activation. To address the relevance of virally increased HIAP-1 levels for the survival of HTLV-1-transformed cells, its expression was RNA interference (RNAi) suppressed using a lentiviral transduction system. This resulted in a dramatic reduction of cell growth, a strong induction of apoptosis rates, and increased caspases 3/7 activity, which is known to be suppressed by HIAP-1. Thus, the Tax-mediated HIAP-1 overexpression is required to suppress endogenous apoptosis and, therefore, is essential for the survival of HTLV-1-transformed lymphocytes. Moreover, this points to HIAP-1 as an important target of the HTLV-1-mediated NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467195     DOI: 10.1182/blood-2005-08-3138

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 2.  Effect of transforming viruses on molecular mechanisms associated with cancer.

Authors:  Tajhal Dayaram; Susan J Marriott
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

3.  Complex cell cycle abnormalities caused by human T-lymphotropic virus type 1 Tax.

Authors:  Liangpeng Yang; Naoe Kotomura; Yik-Khuan Ho; Huijun Zhi; Sandra Bixler; Michael J Schell; Chou-Zen Giam
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

4.  Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1.

Authors:  Andrea K Kress; Grit Schneider; Klemens Pichler; Martina Kalmer; Bernhard Fleckenstein; Ralph Grassmann
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

Review 5.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

Review 6.  Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.

Authors:  S Fulda
Journal:  Leukemia       Date:  2014-02-03       Impact factor: 11.528

Review 7.  Targeting the apoptosis pathway in hematologic malignancies.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2014-02-04

Review 8.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

9.  Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle.

Authors:  Meihong Liu; Liangpeng Yang; Ling Zhang; Baoying Liu; Randall Merling; Zheng Xia; Chou-Zen Giam
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

Review 10.  Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis.

Authors:  Masaya Higuchi; Masahiro Fujii
Journal:  Retrovirology       Date:  2009-12-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.